Affordable Access

Publisher Website

Visual Loss Complicating OKT3 Monoclonal Antibody Therapy

Authors
Journal
American Journal of Ophthalmology
0002-9394
Publisher
Elsevier
Identifiers
DOI: 10.1016/s0002-9394(14)73648-7
Disciplines
  • Medicine

Abstract

OKT3 is a murine monoclonal antibody used for immunosuppression of solid-organ transplant rejection. We studied severe visual loss after administration of OKT3 in two patients who received renal transplants (one 25-year-old woman with interstitial nephritis and severe hypertension and one 27-year-old woman with diabetic nephropathy). Both patients lost visual acuity to the level of light perception after a second or third dose of OKT3. Ophthalmoscopy disclosed arteriolar constriction, but there was no evidence of optic atrophy. The electroretinogram was extinguished in one patient, indicating an effect on the outer retina or retinal pigment epithelium. Ophthalmologists should be aware that OKT3 may cause profound visual loss in patients who receive organ transplants.

There are no comments yet on this publication. Be the first to share your thoughts.

Statistics

Seen <100 times
0 Comments

More articles like this

Visual loss complicating OKT3 monoclonal antibody...

on American journal of ophthalmol... Jun 15, 1993

Visual loss complicating OKT3 monoclonal antibody...

on Nephrology Dialysis Transplant... November 1995

OKT3 monoclonal antibody therapy and visual loss.

on Nephrology Dialysis Transplant... July 1996
More articles like this..